Bioblast Pharma Reports Fourth Quarter and Year End 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
58
Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq: ORPN ), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the fourth quarter ended December 31, 2016 and other recent developments.

Key Corporate Developments:

  • Completed clinical trials: As previously announced on January 18, 2017, the Company reported the results of a six-month open label Phase 2a clinical trial that also included an additional six-month follow-up period investigating trehalose in patients with Spinocerebellar Ataxia Type 3 (SCA3).
  • Departure of members of the Board of Directors : Messrs. Udi Gilboa and Gili Cohen resigned from our Board of Directors effective January 2, 2017 and January 15, 2017, respectively, for personal reasons. Following the resignations, the Board of Directors currently consists of nine members.

Fourth Quarter and Year End 2016 Financial results and Cash Guidance

  • R&D Expenses : Research and development expenses were $1.8 million for the quarter ended December 31, 2016, compared to $1.9 million for the same period in 2015. The research and development expenses for the fourth quarter of 2016 included clinical development activities with respect to completed clinical studies as well as initiation activities with respect to an upcoming Phase 2b double-blind placebo-controlled clinical trial of our trehalose 90mg/mL IV solution (“Trehalose IV”) in oculopharyngeal muscular dystrophy (“OPMD”) patients (the “Phase 2b Trial”). For the year ended December 31, 2016, research and development expenses totaled $8.9 million compared to $7.7 million in the prior year. The increase was primarily due to increased salaries and related expenses including share-based compensation expenses, as well as initiation activities with respect to the Phase 2b Trial.
  • Pre-commercialization Expenses : Pre-commercialization expenses were $0.2 million for the quarter ended December 31, 2016, compared to $0.6 million for the same period in 2015. The decrease was primarily related to the decision to halt spending in this area until our Chief Commercial Officer, who joined in the middle of the quarter, had an opportunity to assess activities in this area. For the year ended December 31, 2016, pre-commercialization expenses totaled $1.1 million, compared to $0.8 million in the prior year. The increase was primarily due to increased market research activities in the first half of the year directed at assessing the commercial opportunity presented by our Trehalose IV solution for the treatment of OPMD and SCA3 patients, which was offset by the reversal of previously recognized share-based compensation due to the forfeiture of options previously granted to departing employees.
  • G&A Expenses: General and administrative expenses were $1.1 million for the quarter ended December 31, 2016, compared to $2.4 million for the same period in 2015. The decrease was primarily related to downsizing the management team, which took effect primarily in the second quarter of 2016. For the year ended December 31, 2016, general and administrative expenses totaled $5.9 million, compared to $7.0 million in the prior year. The general and administrative costs during 2016 included termination related payments to departing employees. Such termination related payments were partially offset by a reversal of previously recognized share-based compensation due to the forfeiture of options previously granted to departing employees.
  • Net Loss : For the quarter ended December 31, 2016, net loss attributable to holders of ordinary shares was ($3.1) million, or ($0.19) per basic and diluted share, as compared to a net loss of ($4.8) million, or ($0.34) per share, for the same period in 2015.
  • Cash Position : Cash, cash equivalents and short-term bank deposits as of December 31, 2016 were $9.9 million, compared to $12.9 million as of September 30, 2016, primarily reflecting the Company’s fourth quarter operating expenditures. Additional funding beyond our existing cash resources will be required to entirely cover the cost of the Phase 2b Trial and the underlying expenses of our operations while the study is ongoing. Should we be unable to obtain the additional funding required to complete our clinical activity, we may need to reduce our activities until we have sufficient resources.

About Bioblast

Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.  Bioblast is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit our website: www.BioblastPharma.com , the content of which is not incorporated herein by reference.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss future clinical studies, the design and timing of such studies, and the Company’s expectation for its cash, cash equivalents and short-term bank deposits need to raise additional funds and sufficiency of financial resources. In addition, historic results of scientific research and clinical and preclinical studies do not guarantee that the conclusions of future research or studies will suggest identical or similar conclusions or that historic results referred to in this press release be interpreted differently in light of additional research and clinical and preclinical study results. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Because such statements deal with future events and are based on Bioblast Pharma's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Bioblast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading "Risk Factors" in Bioblast Pharma's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 29, 2016, and in any subsequent filings with the SEC. Except as otherwise required by law, Bioblast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 

Bioblast Pharma Ltd.
 
Consolidated Statement of Operations
 
 (U.S. dollars in thousands, except share and per share amounts)
 
      Three months ended December 31,   Year ended December 31,  
        2016       2015       2016       2015    
                                     
      U.S. dollars in thousands, except share and per share data  
                     
Research and development     $   1,791     $   1,887     $   8,881     $   7,694    
Pre-commercialization         210         563         1,085         829    
General and administrative         1,073         2,383         5,900         6,953    
Total operating expenses         3,074         4,833         15,866         15,476    
Loss from operations         (3,074 )       (4,833 )       (15,866 )       (15,476 )  
                     
Financial income, net         11         20         60         135    
                     
Loss before taxes on income         (3,063 )       (4,813 )       (15,806 )       (15,341 )  
                     
Taxes on income         (10 )       (16 )       (216 )       (24 )  
                     
Net loss      $   (3,073 )   $   (4,829 )   $   (16,022 )   $   (15,365 )  
                     
Net loss attributable to Ordinary shareholders     $   (3,073 )   $   (4,829 )   $   (16,022 )   $   (15,365 )  
                     
Net loss per share attributable to Ordinary shareholders - basic and diluted     $   (0.19 )   $   (0.34 )   $   (1.01 )   $   (1.08 )  
   
Weighted average number of Ordinary shares outstanding - basic and diluted         16,391,770         14,230,480         15,906,220         14,230,480    
                     

 

Bioblast Pharma Ltd.
 
Consolidated Balance Sheet Data
 
    December 31,      
      2016       2015        
                       
    U.S. dollars in thousands, except share data      
ASSETS              
CURRENT ASSETS:              
Cash and cash equivalents   $   6,871     $   7,286        
Short-term bank deposits       3,007         12,046        
Receivables and prepaid expenses       663         1,060        
Total current assets       10,541         20,392        
               
LONG-TERM ASSETS:              
Long-term assets       18         33        
Property and equipment, net       71         91        
Total long-term assets       89         124        
               
TOTAL ASSETS   $     10,630     $     20,516        
               
LIABILITIES AND SHAREHOLDERS' EQUITY              
CURRENT LIABILITIES:              
Trade payables   $   700     $   1,412        
Other accounts payable       1,231         1,102        
Total current liabilities       1,931         2,514        
               
               
LONG-TERM LIABILITIES       -         70        
               
SHAREHOLDERS' EQUITY:              
Ordinary shares of NIS 0.01 par value - 50,000,000 shares authorized at December 31, 2016 and 2015; 16,391,770 and 14,230,480 issued and outstanding shares at December 31, 2016 and 2015, respectively       45         39        
Additional paid-in capital       48,463         41,680        
Accumulated deficit       (39,809 )       (23,787 )      
Total stockholders' equity       8,699         17,932        
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY   $     10,630     $     20,516        
               
               

 

Bioblast Pharma Ltd.
 
Consolidated Cash Flow Data
   
      Year ended December 31,    
      2016       2015      
              U.S. dollars in thousands    
Cash flows from operating activities            
  Net loss   $   (16,022 )   $   (15,365 )    
  Adjustments to reconcile net loss to net cash used in operating activities:            
  Depreciation and disposal of property and equipment       38         17      
  Share based compensation       700         2,623      
  Interest on short-term deposit       39         (18 )    
  Changes in operating assets and liabilities:            
  Decrease (increase) in receivables and prepaid expenses        399         (786 )    
  Decrease (increase) in long-term assets       13         (24 )    
  Increase (decrease) in trade payables       (712 )       127      
  Increase in other accounts payable       129         107      
  Increase (decrease) in long-term liabilities       (70 )       70      
             
Net cash used in operating activities     (15,486 )     (13,249 )    
             
Cash flow from investing activities            
             
  Withdrawal of (investment in) short-term bank deposits       9,000         10,000      
  Purchase of property and equipment       (18 )       (48 )    
Net cash provided by (used in) investing activities       8,982         9,952      
             
Cash flow from financing activities            
             
  Issuance of shares and warrants, net       6,089         -      
Net cash provided by financing activities       6,089         -      
             
Increase (decrease) in cash and cash equivalents       (415 )       (3,297 )    
Cash and cash equivalents, beginning of the year       7,286         10,583      
             
Cash and cash equivalents, end of the year   $   6,871     $   7,286      
             
Supplemental disclosures of cash flow information:            
Cash paid for taxes   $   210     $   4      
Cash received for interest   $   120     $   162      
             

INVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC Matthew@lifesciadvisors.com Phone:  212-915-0685

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 258

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 145

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 60

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 39

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Alter Predictions for Texas Instruments Earnings Release

Updated Category News Views 48

Analysts Update Forecasts for Texas Instruments Earnings Texas Instruments Incorporated (NASDAQ: TXN) is set to unveil its third-quarter earnings results, scheduled for release after the market closes on a Tuesday evening. Investors are keenly anticipating the outcome as industry buzz suggests that earnings could reflect a notable change from previous figures. Current...

Continue Reading
Iris Energy Limited: Understanding Investor Rights and Legal Options

Updated Category News Views 117

Understanding Your Rights as an Investor in Iris Energy Limited As an investor in Iris Energy Limited, it’s essential to know your rights, especially during challenging times. The legal landscape surrounding securities can be complex, and having informed legal support is crucial. Many investors are unaware of their options and the potential to recover losses stemming...

Continue Reading
McKesson Corporation Set to Release Earnings This November

Updated Category News Views 108

McKesson Corporation's Second Quarter Earnings Announcement McKesson Corporation (NYSE: MCK) is preparing to release its earnings report for the second quarter of fiscal 2025, which will happen after the market closes. Investors and stakeholders can expect to see the detailed financial results made public on a Wednesday. This announcement is a significant moment for the...

Continue Reading
Advantech's Innovations at Medical AI Solutions Conference

Updated Category News Views 122

Advantech Unveils Cutting-Edge Medical AI Solutions Advantech, a renowned global leader in industrial IoT and edge computing solutions, is excited to announce its presence at the MedTech Conference, an event that gathers leading figures in healthcare technology to discuss innovations shaping the future of patient care. Attendees will find Advantech at Booth #1007,...

Continue Reading
Canada's Defence Investment Spurs Innovation and Growth for Draganfly

Updated Category News Views 236

Canada's Defence Investment: A New Era for Technological Advancement In a bold effort to enhance national security, the Canadian government has revealed a significant long-term defence investment package worth $80 billion. This strategic move, championed by Prime Minister Mark Carney, is designed to advance technological capabilities in defence, bolster domestic...

Continue Reading